Change in α 1 HDL Concentration Predicts Progression in Coronary Artery Stenosis
Open Access
- 1 May 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 23 (5) , 847-852
- https://doi.org/10.1161/01.atv.0000066133.32063.bb
Abstract
Objective— We examined the effects of simvastatin-niacin and antioxidant vitamins on changes in high-density lipoprotein (HDL) subpopulations and alterations in coronary artery stenosis, as assessed by angiography. Methods and Results— Lipids, lipoproteins, and HDL particles were measured on and off treatment in 123 subjects of the HDL-Atherosclerosis Treatment Study. Patients were assigned to 4 treatment groups, simvastatin-niacin, simvastatin-niacin-antioxidant vitamins, antioxidant vitamins, and placebo. Subjects were followed for 3 years on treatment and then for 2 months off treatment. Simvastatin-niacin significantly increased the 2 large apoA-I–containing HDL subpopulations, α 1 and preα 1 , and significantly decreased the 2 smallest particles, preβ 1 and α 3 , compared with values obtained from the same patients off treatment. Adding antioxidant vitamins to the lipid-modifying agents blunted these effects (not significant). A significant negative correlation ( r =−0.235; P 1 HDL particle concentration and coronary artery stenosis was noted. Subjects in the third tertile (157% increase in α 1 ) had no progression of stenosis in the 3-year follow-up period, whereas subjects in the first tertile (15% decrease in α 1 ) had an average of 2.1% increase in stenosis. Conclusions— Simvastatin-niacin therapy significantly increased the large apoA-I–containing α 1 HDL particles. This increase was significantly associated with less progression of coronary stenosis even after adjusting for traditional risk factors.Keywords
This publication has 15 references indexed in Scilit:
- Prevention of coronary heart disease by raising high-density lipoprotein cholesterol?Current Opinion in Lipidology, 2000
- Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients With Diabetes and Peripheral Arterial DiseaseJAMA, 2000
- Physiological role and clinical relevance of high-density lipoprotein subclassesCurrent Opinion in Lipidology, 1994
- Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gelsClinica Chimica Acta; International Journal of Clinical Chemistry, 1993
- Two-dimensional electrophoresis of plasma lipoproteins: Recognition of new apo A-I-containing subpopulationsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993
- Regulation of the concentration of pre.beta. high-density lipoprotein in normal plasma by cell membranes and lecithin-cholesterol acyltransferase activityBiochemistry, 1992
- Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: the framingham offspring studyThe American Journal of Medicine, 1991
- Early incorporation of cell-derived cholesterol into pre-.beta.-migrating high-density lipoproteinBiochemistry, 1988
- Subpopulations of apolipoprotein A-I in human high-density lipoproteins their metabolic properties and response to drug therapyBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1983
- PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASEThe Lancet, 1975